Genetically Modified Probiotic Bacteria for GABA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and inflammatory disorders associated with low GABA levels or impaired GABA receptor-mediated signaling are inadequate, as natural sources of GABA are insufficient to provide therapeutic levels.
Innovation Solution
Genetically modified probiotic bacteria, such as Lactococcus lactis, engineered to produce enhanced levels of GABA by expressing glutamic acid decarboxylase and a glutamate/GABA antiporter, are used to increase GABA production and delivery to the body, either through oral compositions or dairy products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural sources of GABA are used, then safety and naturalness are improved, but therapeutic efficacy is insufficient due to low GABA levels
Solution Approach 1:
The patent changes the biological state of the bacteria by introducing heterologous genes (gadB and gadC) to enable GABA production. This genetic modification transforms the bacteria from non-GABA-producing to high-GABA-producing organisms, achieving therapeutic levels while maintaining the natural biological system.
Solution Approach 2:
The probiotic bacteria are engineered to autonomously produce and secrete GABA in the gastrointestinal tract without requiring external administration. The bacteria serve themselves by using their metabolic machinery to convert glutamate to GABA and actively transport it across cell membranes, providing continuous local therapy.
2Quantity of substance
If genetically modified bacteria are used to produce high levels of GABA, then therapeutic efficacy is improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The genetic modification is divided into separate functional modules: the gadB gene encoding glutamic acid decarboxylase enzyme, the gadC gene encoding the GABA/glutamate antiporter, and appropriate promoters for expression. These modular components can be independently optimized and assembled into the bacterial genome systematically.
Solution Approach 2:
The patent uses plasmids as intermediary vectors to introduce and maintain the heterologous genes in the probiotic bacteria. These plasmids serve as temporary carriers that facilitate the transfer of genetic material and can be later integrated into the bacterial chromosome or maintained autonomously, simplifying the manufacturing process.
3Ease of operation
If oral compositions with genetically modified bacteria are administered, then GABA delivery to the body is improved, but reliability of GABA absorption and effectiveness is uncertain
Solution Approach 1:
The patent creates a biological factory (genetically modified probiotic bacteria) that replicates and persists in the gastrointestinal tract. These bacteria continuously produce GABA locally, effectively copying the therapeutic function multiple times as the bacterial population grows and maintains itself in the gut environment.
Solution Approach 2:
The bacteria act as living intermediaries that convert dietary glutamate into GABA within the gastrointestinal tract and actively transport it across the intestinal epithelium. This biological mediation ensures reliable delivery of GABA to the bloodstream, overcoming the limitations of direct oral GABA administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically modified probiotic bacteria significantly increase GABA levels, providing therapeutic benefits for neurological and inflammatory disorders by reducing inflammation and improving immune system function, as demonstrated in mouse models of multiple sclerosis and irritable bowel disease.
Implementation Method 1
expression of glutamic acid decarboxylase
Implementation Method 2
expression of a glutamate/GABA antiporter
Data Source
AI summary
Probiotic bacteria are genetically modified to produce and excrete enhanced levels of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Exemplary probiotic bacteria include Lactococcus lactis (L. lactis). The genetically modified probiotic bacteria can be prepared as an aqueous suspension and/or incorporated into food and nutraceuticals for oral administration to a subject. An oral formulation including the genetically modified probiotic bacteria can be used to treat inflammatory diseases and/or behavioral disorders caused by or associated with GABA-GABA signaling deficiency or by excess of excitatory neurotransmitters (such as glutamate). Inflammatory conditions that can be treated with the genetically modified probiotic bacteria include multiple sclerosis (MS) and irritable bowel disease (IBD).